Introduction {#sec1-1}
============

Sarcoidosis is a systemic granulomatous disease that mainly affects the lungs and the lymphatics but any organ or system can be involved ([@ref1]). The disease may go into remission spontaneously or upon treatment but it has a chronic course in about 25% of the patients. Corticosteroids (CS) are the mainstay of treatment but their long-term use is hindered by a cumulative toxicity ([@ref1]). The efficacy of hydroxychloroquine, methotrexate (MTX), azathioprine (AZA), mycophenolate mofetil (MMF), leflunomide (LEF) and cyclophosphamide (CYC) as adjunctive or alternative therapies has been reported ([@ref2]).

Because some patients are non responsive to these therapies or may develop adverse events, tumor necrosis factor (TNF) antagonists have been proposed as a third-line option ([@ref3]). Several retrospective studies have reported the efficacy of TNF antagonists for the treatment of sarcoidosis ([@ref4]-[@ref10]). In a previous retrospective multicentric study, the STAT (Sarcoidosis Treated with Anti-TNF) study, reporting on 132 sarcoidosis patients treated with TNF antagonists, we found that TNF antagonists were efficient in about two-thirds of the patients and allowed a substantial reduction in prednisone dosages (from 23 to 11 mg/day) ([@ref11]).

Although some patients do not respond to TNF antagonists ([@ref12]), there is no data in the literature regarding the characteristics of these patients, the outcome and the subsequent treatment options.

Thus, our aim was to describe patients included in our registry who did not respond to TNF antagonists.

Methods {#sec1-2}
=======

Patients from the French STAT registry were previously described ([@ref11]). Patients who were classified as non-responders to TNF antagonists (clinical or radiological progression) and who were followed-up for more than one year were included.

Patients were not included if the outcome was not reported. Special attention was held to exclude differential diagnoses such as tuberculosis, other mycobacterial infections, Whipple's disease, Crohn's disease and lymphoma.

The response to therapies was classified as complete response (CR), or partial response (PR). Complete response was defined as a resolution at any time of clinical signs along with a CS dosage \<10 mg/day. Partial response was defined as an improvement in clinical and paraclinical parameters and a reduction of \>50% of initial corticosteroid dosages. Other patients were classified as non-responders (NR, stable or progressive disease).

Results {#sec1-3}
=======

Initial characteristics of patients with a sarcoidosis resistant to TNF antagonists {#sec2-1}
-----------------------------------------------------------------------------------

Among the 132 patients included in the STAT registry, 14 patients had been classified as non-responders to TNF antagonists. Five patients were not included because: (i) three were lost to follow-up; (ii) one patient died; and (iii) one had an alternative final diagnosis.

Nine patients (6 women) were finally included in the study; six were Caucasian, one was North African, one was African, and one was Asian.

The mean age at TNF antagonist initiation was 48 (range, 29-70) years. The disease was severe and the mean number of organs involved was 4.2 ([@ref2]-[@ref7]). 7 patients were previously treated with at least two immunosuppressive therapies ([Table 1](#T1){ref-type="table"}). Eight patients were treated with only one TNF antagonist \[infliximab (IFX), n=8\] while one patient received 3 different TNF antagonists \[etanercept (ETN), IFX, and adalimumab (ADA)\]. The mean duration of treatment was 9 months (range, 3-24). In addition to TNF antagonists, five patients received CS (mean dosage, 34 mg/day) and four patients received an immunosuppressant (IS: MTX, n=2; AZA, n=1; and MMF, n=1).

###### 

Treatments before, during and after TNF antagonists

  Before anti-TNF                                                      During anti-TNF       After anti-TNF                                 Response to treatment
  -------------------------------------------------------------------- --------------------- ---------------------------------------------- -----------------------
  1 MMF, CYC                                                           IFX, AZA              MTX (25 mg/w)                                  PR
  2 MTX, CYC                                                           IFX                   CYC, AZA, RTX, CYC                             PR
  3 MTX (10 mg/w), plaquenil                                           IFX,MTX (20 mg/w)     MTX (25 mg/w), AZA (150 mg/d)                  CR
  4 MTX, CYC                                                           IFX                   CYC, AZA (200 mg/d)                            CR
  5 MTX (15 mg/w), plaquenil, thalidomide                              IFX, MTX (10 mg/w),   MTX (20 mg/w), LEF (20 mg/d)                   PR
  6 MTX (20 mg/w), MMF, plaquenil (400 mg/d), thalidomide (150 mg/d)   IFX, MMF              MTX (20 mg/w), AZA (150 mg/d), LEF (20 mg/d)   PR
  7 MMF (3 g/d), CYC, plaquenil                                        IFX                   MMF (2 g/d), plaquenil, AZA (75 mg/d)          PR
  8 CYC                                                                IFX                   CS                                             NR
  9 MTX                                                                ETN→IFX→ADA           MTX (15 mg/w)                                  NR

ADA, adalimumab; AZA, azathioprine; CS, corticosteroids; CYC, cyclophosphamide; ETN, etanercept; IFX, infliximab, LEF, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; TNF, tumor necrosis factor; RTX, rituximab; CR: complete response; PR: partial response; NR : non-responder

Outcome of patients with a sarcoidosis resistant to TNF antagonists {#sec2-2}
-------------------------------------------------------------------

The mean follow-up duration was 58 months (median, 35; range, 19-128) and patients received a median of 2 IS treatments (range, 0-4), including MTX, CYC, MMF, AZA, LEF, and rituximab ([Figure 1](#F1){ref-type="fig"}).
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MTX was the most frequent first-line IS (n=5) while AZA was more frequently used as a second-line therapy (n=5).

All patients were alive at last follow-up and a CR was observed in two cases, a PR in five cases, and the disease was progressive in two cases.

The first patient had a CR with MTX but had to be switched to AZA because of side-effects. The second patient had a CR with CYC, which was maintained under AZA. Both patients had previously been treated by these IS, but the MTX dosage was increased from 20 to 25 mg/week.

In patients with a PR, all had the same IS as before except for one patient.

The disease was progressive in two cases that were treated by CS only because of their comorbidities or noncompliance to IS treatment.

Discussion {#sec1-4}
==========

In this retrospective study, we describe for the first time the characteristics, outcome and response to therapy of sarcoidosis patients who do not respond to TNF antagonists. Among the 9 patients, 7 had a clinical response (CR or PR) with additional IS therapy. The disease was only progressive in patients treated with CS without adjunctive IS.

Most importantly, the IS that allowed the clinical response had previously been used, except for one patient. Furthermore, the dosage was not necessarily increased to gain efficacy (same galenic and dosage in 4 cases).

IFX has been the most extensively studied TNF antagonist in sarcoidosis ([@ref5], [@ref12]-[@ref18]) and is considered as the main anti-TNF treatment for refractory sarcoidosis. Nevertheless, several open-label studies have also shown that ADA was efficient for skin, ocular or pulmonary sarcoidosis ([@ref9], [@ref17]). Crommelin et al. have reported the efficacy of ADA in 39% of sarcoidosis patients who developed an intolerance or a resistance to IFX ([@ref10]). In other inflammatory diseases, it has been shown that patients who have anti-infliximab antibodies have an increased risk of infusion reactions and a 3-fold higher risk of losing clinical response ([@ref19]-[@ref22]). Switching from one anti-TNF to another may thus be a reasonable strategy, mostly for ETN because immunization against this fusion protein is much less frequent. Unfortunately, in our multicentric retrospective study, we did not have data describing immunization against IFX because anti-IFX antibodies were not systematically tested. Moreover, we cannot exclude noncompliance to explain the initial resistance to IS in our patients since drug dosages were not performed.

Although the number of patients included may seem small, the data was recorded as part of the STAT registry, which is the largest cohort of patients with sarcoidosis treated with TNF antagonists. Further larger studies are warranted to confirm our findings.

Conclusion {#sec1-5}
==========

Our study reports for the first time the outcome of sarcoidosis patients refractory to TNF antagonists. The prognosis was good for the majority of the patients who were treated with IS. Most importantly, the dosage and galenic were not systematically modified indicating that, when sarcoidosis remains refractory to TNF antagonists, treating with previously used IS may still be useful. Excluding a differential diagnosis, assessing compliance, and testing for anti-drug antibodies should be systematic before classifying patients as non-responders. Finally, switching to another TNF antagonist could be useful.
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